HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1- (2,4- dichlorophenyl)- 4- ethyl- 5- (5- (2- phenylethynyl)thiophen- 2- yl)- N- (piperidin- 1- yl)- 1H- pyrazole- 3- carboxamide

Also Known As:

BPR697

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-phenylethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide: 1
  - Thiophenes: 257
    - 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-phenylethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide: 1
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-phenylethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide: 1

Experts

1.	Chang, C-P: 1 article (07/2012)
2.	Chao, Y-S: 1 article (07/2012)
3.	Hsiao, W-C: 1 article (07/2012)
4.	Hsieh, W-P: 1 article (07/2012)
5.	Hung, M-S: 1 article (07/2012)
6.	Lin, Y: 1 article (07/2012)
7.	Shia, K-S: 1 article (07/2012)
8.	Vijayakumar, R S: 1 article (07/2012)
9.	Yeh, Y-N: 1 article (07/2012)

Related Diseases

1.	Weight Loss (Weight Reduction) 07/01/2012 - "When administered to rats at 20 mg kg(-1), BPR697 showed a unique spectrum of effects with significant weight loss without altered food intake. " 07/01/2012 - "The induction of fatty acid oxidation without concomitant elevation of energy expenditure by the peripheral CB1 antagonist BPR697 is sufficient to cause substantial weight loss in chow-fed rats. "
2.	Weight Gain 07/01/2012 - "In DIO mice with chronic treatment, animals treated with BPR697 at 20 mg kg(-1) resisted weight gain and showed a reduction of high-fat-induced cardiometabolic abnormalities such as hyperglycemia, abdominal fat and liver steatosis. " 07/01/2012 - "In the presence of high-dietary fat intake, BPR697 resists weight gain and alleviates obesity-related cardiometabolic risk factors."
3.	Obesity 07/01/2012 - "In the presence of high-dietary fat intake, BPR697 resists weight gain and alleviates obesity-related cardiometabolic risk factors."
4.	Hyperglycemia 07/01/2012 - "In DIO mice with chronic treatment, animals treated with BPR697 at 20 mg kg(-1) resisted weight gain and showed a reduction of high-fat-induced cardiometabolic abnormalities such as hyperglycemia, abdominal fat and liver steatosis. "
5.	Fatty Liver 07/01/2012 - "In DIO mice with chronic treatment, animals treated with BPR697 at 20 mg kg(-1) resisted weight gain and showed a reduction of high-fat-induced cardiometabolic abnormalities such as hyperglycemia, abdominal fat and liver steatosis. "

Related Drugs and Biologics

1.	Fatty Acids (Saturated Fatty Acids)
2.	Dietary Fats (Dietary Fat)